PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93020C00039 — EO14042 TO DEVELOP INNOVATIVE AND SAFE MULTIVALENT ANTI-OPIOID VACCINES THAT PROTECT AGAINST HEROIN AND FENTANYL.

EO14042 TO DEVELOP INNOVATIVE AND SAFE MULTIVALENT ANTI-OPIOID VACCINES THAT PROTECT AGAINST HEROIN AND FENTANYL. is a federal NONE award for Department of Health and Human Services (HHS) held by UNIVERSITY OF MONTANA. Estimated value $25.9M ($15.5M obligated). Current period of performance ends Sep 29, 2027. Last award drew 9 bidders.

$25.9M
Estimated Value
$15.5M
Obligated
Sep 29, 2027
PoP End / Expires
9
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

UNIVERSITY OF MONTANA holds $46.8M across 59 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 9 offers. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75N93020C00039
AgencyDepartment of Health and Human Services (HHS)
IncumbentUNIVERSITY OF MONTANA
UEIDAY7Z8ZD48Q3
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12
PoP end (current)Sep 29, 2027
Obligated$15.5M

EO14042 TO DEVELOP INNOVATIVE AND SAFE MULTIVALENT ANTI-OPIOID VACCINES THAT PROTECT AGAINST HEROIN AND FENTANYL.

Recompete timing

Public
Expiring in 408 days

Current PoP ends Sep 29, 2027 (408 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Watch this contract — one email →

Incumbent footprint

Public record

UNIVERSITY OF MONTANA$46.8M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($46.8M) · all agencies
Department of Health and Human Services (HHS)$28.0M · 60%Department of Defense (DOD)$14.2M · 30%
Department of Commerce (DOC)$3.7M · 8%
Department of the Interior (DOI)$879K · 2%
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75N93020C00039
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open UNIVERSITY OF MONTANA’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N93020C00039?

75N93020C00039 (EO14042 TO DEVELOP INNOVATIVE AND SAFE MULTIVALENT ANTI-OPIOID VACCINES THAT PROTECT AGAINST HEROIN AND FENTANYL.) is a Department of Health and Human Services (HHS) award with an estimated value of $25.9M, currently held by UNIVERSITY OF MONTANA. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N93020C00039?

UNIVERSITY OF MONTANA is the incumbent with $46.8M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does 75N93020C00039 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N93020C00039